These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18284688)

  • 21. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
    Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
    Ramus SJ; Kartsonaki C; Gayther SA; Pharoah PD; Sinilnikova OM; Beesley J; Chen X; McGuffog L; Healey S; Couch FJ; Wang X; Fredericksen Z; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Allavena A; Ottini L; Papi L; Gismondi V; Capra F; Radice P; Greene MH; Mai PL; Andrulis IL; Glendon G; Ozcelik H; ; Thomassen M; Gerdes AM; Kruse TA; Cruger D; Jensen UB; Caligo MA; Olsson H; Kristoffersson U; Lindblom A; Arver B; Karlsson P; Stenmark Askmalm M; Borg A; Neuhausen SL; Ding YC; Nathanson KL; Domchek SM; Jakubowska A; Lubiński J; Huzarski T; Byrski T; Gronwald J; Górski B; Cybulski C; Dębniak T; Osorio A; Durán M; Tejada MI; Benítez J; Hamann U; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Bodmer D; Ausems MG; van Os TA; Asperen CJ; Blok MJ; Meijers-Heijboer HE; ; ; Peock S; Cook M; Oliver C; Frost D; Dunning AM; Evans DG; Eeles R; Pichert G; Cole T; Hodgson S; Brewer C; Morrison PJ; Porteous M; Kennedy MJ; Rogers MT; Side LE; Donaldson A; Gregory H; Godwin A; Stoppa-Lyonnet D; Moncoutier V; Castera L; Mazoyer S; Barjhoux L; Bonadona V; Leroux D; Faivre L; Lidereau R; Nogues C; Bignon YJ; Prieur F; Collonge-Rame MA; Venat-Bouvet L; Fert-Ferrer S; ; Miron A; Buys SS; Hopper JL; Daly MB; John EM; Terry MB; Goldgar D; ; Hansen Tv; Jønson L; Ejlertsen B; Agnarsson BA; Offit K; Kirchhoff T; Vijai J; Dutra-Clarke AV; Przybylo JA; Montagna M; Casella C; Imyanitov EN; Janavicius R; Blanco I; Lázaro C; Moysich KB; Karlan BY; Gross J; Beattie MS; Schmutzler R; Wappenschmidt B; Meindl A; Ruehl I; Fiebig B; Sutter C; Arnold N; Deissler H; Varon-Mateeva R; Kast K; Niederacher D; Gadzicki D; Caldes T; de la Hoya M; Nevanlinna H; Aittomäki K; Simard J; Soucy P; ; Spurdle AB; Holland H; Chenevix-Trench G; Easton DF; Antoniou AC;
    J Natl Cancer Inst; 2011 Jan; 103(2):105-16. PubMed ID: 21169536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
    Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
    Claus EB; Petruzella S; Matloff E; Carter D
    JAMA; 2005 Feb; 293(8):964-9. PubMed ID: 15728167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
    Tazzite A; Jouhadi H; Nadifi S; Aretini P; Falaschi E; Collavoli A; Benider A; Caligo MA
    Gynecol Oncol; 2012 Jun; 125(3):687-92. PubMed ID: 22425665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
    Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
    J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer.
    Choi MC; Jang JH; Jung SG; Park H; Joo WD; Song SH; Lee C; Lee JH
    Int J Gynecol Cancer; 2018 Feb; 28(2):308-315. PubMed ID: 29240602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
    Bergthorsson JT; Ejlertsen B; Olsen JH; Borg A; Nielsen KV; Barkardottir RB; Klausen S; Mouridsen HT; Winther K; Fenger K; Niebuhr A; Harboe TL; Niebuhr E
    J Med Genet; 2001 Jun; 38(6):361-8. PubMed ID: 11389159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
    Akbari MR; Zhang S; Fan I; Royer R; Li S; Risch H; McLaughlin J; Rosen B; Sun P; Narod SA
    J Med Genet; 2011 Nov; 48(11):783-6. PubMed ID: 21965345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
    Peto J; Collins N; Barfoot R; Seal S; Warren W; Rahman N; Easton DF; Evans C; Deacon J; Stratton MR
    J Natl Cancer Inst; 1999 Jun; 91(11):943-9. PubMed ID: 10359546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.